Advocate Group LLC Trims Position in Johnson & Johnson $JNJ

Advocate Group LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,469 shares of the company’s stock after selling 3,655 shares during the quarter. Johnson & Johnson makes up about 2.2% of Advocate Group LLC’s holdings, making the stock its 5th biggest holding. Advocate Group LLC’s holdings in Johnson & Johnson were worth $13,756,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $41,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target to $285 and kept a “buy” rating, implying roughly 20% upside from recent levels — a notable analyst vote of confidence for JNJ’s outlook. Read More.
• Positive Sentiment: Guggenheim also nudged up its target to $244 and maintained a “buy” rating, adding incremental analyst support for the stock. Read More.
• Positive Sentiment: JNJ received CE‑Mark clearance and launched the next‑gen VARIPULSE Pro PFA catheter in Europe — a commercial milestone that should support MedTech sales growth in international markets. Read More.
• Positive Sentiment: Specialty therapy updates: JNJ secured a permanent US reimbursement code for bladder cancer drug INLEXZO, reported 52‑week efficacy for ICOTYDE in psoriasis, and struck an exclusive Japan distribution deal for SIRTURO (drug‑resistant TB). These moves improve commercial visibility and address previous undervaluation arguments. Read More.
• Neutral Sentiment: Technical / timing note: Dow Jones/Investors.com flagged JNJ as in or near a buy zone — bullish from a trading setup perspective but not a fundamental catalyst. Read More.
• Neutral Sentiment: Analyst consensus remains around “Moderate Buy,” reflecting broad analyst support but not unanimous enthusiasm; watch for further analyst commentary and earnings updates. Read More.
• Neutral Sentiment: Longer‑term comparison pieces (e.g., JNJ vs KO) highlight JNJ’s dividend durability and oncology growth but don’t present immediate price catalysts. Read More.

Johnson & Johnson Price Performance

NYSE JNJ opened at $238.47 on Wednesday. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The stock has a 50-day moving average of $240.53 and a 200 day moving average of $214.17. The company has a market capitalization of $574.38 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 2.41 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on JNJ shares. The Goldman Sachs Group restated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a report on Thursday, January 22nd. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Rothschild & Co Redburn raised their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $237.57.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last three months. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.